指南与共识痛风与晶体性关节病

G-CAN关于痛风疾病状态标签与定义的共识声明

Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout.
指南 / 共识 · Ann Rheum Dis · 2019-09-09

G-CAN通过内容分析、Delphi调查和面对面共识会议,为痛风疾病状态制定标签与定义共识。内容分析识别13种疾病状态和63个标签,最终对8种疾病状态标签及定义达成共识,并建议在研究及临床实践中使用这些标签。

要点

  • 共识确定8种痛风疾病状态标签及定义,包括无症状高尿酸血症、无症状MSU晶体沉积、痛风等。
  • 「痛风」标签应仅限用于当前或既往由MSU晶体沉积引起的临床明显疾病。
  • G-CAN推荐在研究及临床实践中使用这些共识标签描述痛风疾病状态。

核心结论

  • G-CAN对8种痛风疾病状态标签及定义达成共识,包括「痛风」本身,并推荐在研究及临床实践中使用。

研究设计与样本

  • 对5年内风湿病学和普通内科学期刊发表的痛风相关文章进行内容分析,识别潜在疾病状态及常用标签。
  • 基于内容分析结果,邀请痛风专家参与Delphi调查(n=76名应答者)和面对面共识会议(n=35名参会者)以达成标签与定义共识。

主要发现

  • 内容分析识别13种独特疾病状态和共63个独特标签。
  • Delphi调查和面对面会议对8种疾病状态标签及定义达成共识。
  • 达成共识的标签为:无症状高尿酸血症、无症状单钠尿酸盐晶体沉积、无症状高尿酸血症伴单钠尿酸盐晶体沉积、痛风、痛风石性痛风、侵蚀性痛风、首次痛风发作和复发性痛风发作。
  • 共识同意「痛风」标签应仅限用于当前或既往由单钠尿酸盐晶体沉积引起的临床明显疾病(痛风发作、慢性痛风性关节炎或皮下痛风石)。

关键数值与推荐

  • Delphi调查应答者76名,面对面会议参会者35名。
  • 内容分析识别13种独特疾病状态和63个独特标签。
  • 共识确定8种疾病状态标签及定义。

临床怎么用

  • G-CAN推荐在研究及临床实践中使用这些共识标签描述痛风疾病状态。
  • 「痛风」标签应仅限用于当前或既往由MSU晶体沉积引起的临床明显疾病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There is a lack of standardisation in the terminology used to describe gout. The aim of this project was to develop a consensus statement describing the recommended nomenclature for disease states of gout. METHODS: A content analysis of gout-related articles from rheumatology and general internal medicine journals published over a 5-year period identified potential disease states and the labels commonly assigned to them. Based on these findings, experts in gout were invited to participate in a Delphi exercise and face-to-face consensus meeting to reach agreement on disease state labels and definitions. RESULTS: The content analysis identified 13 unique disease states and a total of 63 unique labels. The Delphi exercise (n=76 respondents) and face-to-face meeting (n=35 attendees) established consensus agreement for eight disease state labels and definitions. The agreed labels were as follows: 'asymptomatic hyperuricaemia', 'asymptomatic monosodium urate crystal deposition', 'asymptomatic hyperuricaemia with monosodium urate crystal deposition', 'gout', 'tophaceous gout', 'erosive gout', 'first gout flare' and 'recurrent gout flares'. There was consensus agreement that the label 'gout' should be restricted to current or prior clinically evident disease caused by monosodium urate crystal deposition (gout flare, chronic gouty arthritis or subcutaneous tophus). CONCLUSION: Consensus agreement has been established for the labels and definitions of eight gout disease states, including 'gout' itself. The Gout, Hyperuricaemia and Crystal-Associated Disease Network recommends the use of these labels when describing disease states of gout in research and clinical practice.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Bursill D, Taylor WJ, Terkeltaub R, et al. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Ann Rheum Dis. 2019. PMID: 31501138. doi:10.1136/annrheumdis-2019-215933

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。